RESULTS: In AR-positive prostate cancer cell lines, overexpression of wild-type SgI considerably increased cell viability and migration in the presence of high levels (e.g. 100-300 mM) of zinc that was cytotoxic by itself. The wild-type SgI could also interact with AR and enhanced dihydrotestosterone-mediated AR transcription. By contrast, the mutant SgI failed to significantly increase cell proliferation/migration, to interact with AR, and to induce AR transactivation even in the presence of zinc. In addition, transfection of an 18-amino acid peptide of SgI containing LxxLL, but not LxxAA, resulted in significant inhibition of cell proliferation and PSA expression in LNCaP and C4-2 lines.
INTRODUCTION AND OBJECTIVES: BH3 mimetic drugs targeting BCL2 and/or BCLXL (navitoclax and venetoclax) have efficacy in hematological malignancies, but they do not block MCL1, and MCL1 expression may limit their effectiveness in solid tumors. The purpose of this study is to target apoptosis pathway in prostate cancer focusing on MCL1 inhibition in combined with BH3 mimetics.
METHODS: We conducted MCL1 knockdown with siRNA and shRNA and also generated MCL1 knockout prostate cancer cell line. In parallel studies, we screened in vitro a small series of drugs in combination with navitoclax to identify potentially effective combination therapies.
RESULTS: We initially found that MCL1 depletion markedly sensitized prostate cancer cells to navitoclax-mediated apoptosis in vitro and in vivo, indicating that they are primed to undergo apoptosis and protected by MCL1 and BCL2/BCLXL (figure 1). Small molecule EGFR kinase inhibitors (erlotinib, lapatinib) also dramatically sensitized to navitoclax-mediated apoptosis, and this was associated with markedly increased MCL1 degradation (figure 2). Significantly, this MCL1 degradation was not through GSK3b and downstream MCL1 ubiquitin ligases, and was not dependent on other known MCL1 ubiquitin ligases or deubiquitinases. Inhibitors targeting additional kinases (cabozantinib and sorafenib) similarly caused GSK3b-independent MCL1 degradation and synergized with navitoclax in vitro and in vivo.
CONCLUSIONS: These studies indicate that MCL1 stability is regulated by a novel mechanism downstream of receptor tyrosine kinase signaling in epithelial cancers, which may be exploited therapeutically.
Source of Funding: This work was supported by NIH grants P01 CA163227, P50 CA090381, and by a Bridge Project grant from the DF/HCC and Koch Institute.
PD65-10 PRLZ INCREASES PROSTATE CANCER DOCETAXEL RESISTANCE BY INHIBITING LKB1/AMPK-MEDIATED AUTOPHAGY
Jin Zeng*, Wei Liu, Yizeng Fan, Dalin He, Lei Li, Xi'an, China, People's Republic of INTRODUCTION AND OBJECTIVES: Docetaxel-mediated chemotherapy is the first-line standard approach and has been determined to show a survival advantage for metastatic castration-resistant prostate cancer (mCRPC) patients. However, a substantial proportion of patients eventually becomes refractory due to drug resistance. The detailed mechanisms remain unclear. We have previously reported that Prostate Leucine Zipper (PrLZ), a specific oncogene of prostate cancer (PCa), promotes PCa cell growth at the castration-resistant stage, thus suggesting a vital role of PrLZ in the progression of CRPC. In this study, we aimed to investigate the role of PrLZ in docetaxel resistance in PCa, focusing on PrLZ-regulating autophagy pathway.
METHODS: Human PCa PC3, LNCaP and C4-2 cell lines were used as the model system in vitro and PCa xenografts and PrLZknockout mice were used as the model system in vivo. Docetaxelinduced cell death and apoptosis in PCa were determined by MTT and flow cytometry assay. The effects of PrLZ on autophagy were determined by LC3 conversion, LC3 turnover, and LC3-GFP-RFP puncta assay. The role of PrLZ in the regulation of autophagy and liver kinase e1228 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 B1/AMP-activated protein kinase (LKB1/AMPK) signaling pathway was analyzed using immunoblotting, immunoprecipitation, siRNA silencing and plasmid overexpression. RESULTS: PrLZ increased docetaxel-mediated drug resistance in PCa both in vitro and in vivo. PrLZ was involved in both glucose starvation and docetaxel-induced autophagy. Mechanistic dissection revealed that PrLZ interacted with LKB1 and further inhibited the activation of LKB1/AMPK signals, which negatively contributed to the induction of autophagy. Moreover, PrLZ/LKB1-mediated autophagy conferred resistance to docetaxel-induced cell death and apoptosis both in vitro and in vivo.
CONCLUSIONS: These findings identify a novel role of PrLZ in autophagy manipulation and provide new insight into docetaxel chemoresistance in PCa, suggesting a new strategy for treating mCRPC by targeting this newly identified signaling pathway.
Source of Funding: National Natural Science Foundation of China (NO. 81072107, 81130041, 81472679, 81672538 and 81773206) and the National Key Research and Development Program (NO. 2016YFC0902603).
PD65-11 MOLECULAR RATIONALE FOR TARGETING DNA-PKC TO ENHANCE UTILITY OF RADIATION THERAPY IN PROSTATE CANCER
Timothy Clinton*, Yi Yin, Ganesh Raj, Dallas, TX INTRODUCTION AND OBJECTIVES: The combination of radiation therapy (RT) and androgen deprivation therapy (ADT) is superior to RT alone for treatment of patients with clinically localized, intermediate and high-risk prostate cancer. ADT acts to prevent the androgen receptor (AR) from promoting DNA damage repair (DDR), which thereby increases RT-mediated cell kill. Emerging evidence supports that AR variants can mediate DDR following RT allowing for increased cell survival. Further studies have demonstrated that irradiation of prostate cancer cells trigger binding of androgen receptors to the catalytic subunit of the critical DNA repair kinase DNA-PK (DNA-PKc). We set to study if the influence of DNA-PKc in RT-induced DNA damage of prostate cancer cells.
METHODS: Using a prostate cancer cell line and a DNA-PKc inhibitor NU7441, cells were subjected to irradiation (IR) and the amount of damaged DNA was visualized with comet assays. The quantification of DNA damage was further evaluated with quantitative immunofluorescence of gamma-H2AX and 53BP1. To validate these findings in vivo, we established subcutaneous R1-D567 xenografts in Nu/Nu mice. When tumors reached 200mm3, mice were castrated and treated with NU7441, followed by 2Gy radiation. Treatment groups were compared for tumor growth.
RESULTS: Pretreatment with NU7441 enhanced IR DNA damage with increased olive tail movement on comet assay. This was supported by the persistence of double-stranded breaks after IR as shown in Figure 1A . This demonstrated in vitro that DNA-PKc inhibition was associated with increased IR-induced DNA damage.The results of our in vivo model validated our findings. The combination of IR and NU7441 was more effective in slowing the tumor growth than control when assessed by split-plot ANOVA (p<0.001). DNA damage in these cells were again quantified by significant persistence of gamma-H2AX and 53BP1 after IR (p<0.001).
CONCLUSIONS: DNA-PKc is critical for DNA repair mechanisms following IR and that the combined blockade of AR and DNA-PKc enhances IR-mediated cell kill. This data establishes the molecular rationale for a potential clinical trial combining agents targeting DNAPKc in combination with RT for patients with clinically localized prostate cancer. In recent years, it has become evident, that the different cell populations comprising the tumor microenvironment contribute substantially to carcinogenesis, local tumor growth and metastatic spread. Especially the tumor-promoting roles of cancer-associated fibroblasts have been the focus of several elaborate in-vitro studies. However, evidence from representative invivo models is scarce. In this study, we coinjected prostate cancer (PCa) cells together with different populations of prostate fibroblasts (cancer-associated (CAF), not cancer-associated (NCAF), benign prostate hyperplasia associated (BPHF)) and examined their impact on local tumor growth and the development of metastases.
METHODS: We isolated fibroblast primary cultures from tumorbearing (CAF) and tumor-free (NCAF) tissue samples of a radical prostatectomy specimen as well as from tissue samples of a transvesical prostate adenoma enucleation (BPHF). 5x10 5 CAF/NCAF/ BPHF cells were injected into the prostate of SCID mice together with 5x10 5 LuCaP136 spheroids or LNCaP cells (n¼8 for each group). Tumor growth was monitored by ultrasonography, micro-CT, 9.4T MRI and serum PSA-measurements. Animals were sacrificed after 10 weeks.
RESULTS: The coinjection of CAFs fostered tumor growth in LuCaP136 but not in LNCaP xenografts. Primary tumor volumes as well as serum PSA values were significantly higher in LuCaP136þCAF mice compared to LuCaP136þNCAF and LuCaP136þBPHF mice (p<0.01 for each time point). Significantly more lymph node metastases (LN mets) were seen in LuCaP136þCAF mice (one mouse without, four mice with 2 and three mice with ¼3 LN mets) compared to LuCaP136þNCAF (one mouse without, four mice with 1 and one mouse with 2 LN mets) and LuCaP136þBPHF mice (two mice without, three mice with 1 and two mice with 2 LN mets) (p<0.01). Furthermore, pulmonary metastases were observed more often in LuCaP136 and LNCaP xenografts when PCa cells were coinjected with CAFs (57% for LuCaP136, 71% for LNCaP) as compared to coinjection with NCAFs (0% for LuCaP136, 29% for LNCaP) and BPHFs (14% for LuCaP136, 29% for LNCaP).
CONCLUSIONS: Using a representative orthotopic xenograft model and patient-derived fibroblast cultures it could be shown that CAFs play a crucial role in local and systemic PCa progression by stimulating primary tumor growth and metastatic spread to the lymph nodes and lungs. However, some of the effects were cell-line specific.
